Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer Consortium
Lovelace Biomedical
by Research_Facility
4M ago
Pandemic uncertainties cloud nebulizer use. But the COPD Foundation’s CNC offers science-backed guidance to minimize aerosol risks in hospitals and homes, ensuring vital treatments reach patients without compromising safety. Unfounded avoidance harms, so we’re finding ways to make nebulizers shine even in outbreaks. More research needed, but the future’s hopeful for these crucial tools. To read the abstract or download the full paper, visit Chest Journal. The post Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer Consort ..read more
Visit website
Evolving with the FDA Modernization Act
Lovelace Biomedical
by Research_Facility
4M ago
The appropriate utilization of animals within non-clinical research is always on the minds of drug developers. Lovelace Biomedical is always working with its team of experts to stay in touch with the current regulatory landscape and evaluating novel approaches to reduce the number of animals required in drug development. With the recent changes in the FDA Modernization Act Lovelace’s approach continues to evolve and some details can be found in their recent article with AAPS News Magazine: Bringing Clarity and Perspective to the FDA Modernization Act 2.0. The post Evolving with the FDA Modern ..read more
Visit website
Inhalation delivery of nucleic acid gene therapies in preclinical drug development
Lovelace Biomedical
by Research_Facility
6M ago
Inhaled gene therapies hold great promise in treating a number of diseases including cystic fibrosis and certain cancers of the lung, but the development of these types of therapies is immensely challenging. Lovelace Biomedical has been and remains at the forefront in translational research for inhaled gene therapies. In this review article, Lovelace Biomedical aerosol scientists describe several of these challenges based on our experience as a preclinical contract research organization with a long history in inhalation delivery and over 15 years of work supporting gene therapy programs. If yo ..read more
Visit website
Novel bioanalytical approaches to drug development – 5-AZA a case study to be presented at the 67th ASMS Conference in Atlanta
Lovelace Biomedical
by Biotech_Research
6M ago
Within drug development, the quantitation of drug levels within the systemic circulation and target tissues can provide insight into tolerance and / or efficacy. For small molecules the mainstay for quantitative analysis is LC-MS/MS. 5-azacytidine has been used in the treatment of lung cancer, and for years the nucleosidic nature of 5-azacytidine resulted in significant interference with parent compound’s MRM mass transitions. In order to solve this the Lovelace bioanalytical team utilized a novel approach which enabled quantification from plasma and multiple tissues (lung, brain, and liver) w ..read more
Visit website
Lovelace Biomedical Wins 10M to Combat Opioid Overdose
Lovelace Biomedical
by Research_Facility
11M ago
Lovelace Biomedical has recently received 3 new grants and contracts worth over 10 million granted by the National Institutes of Health (NIH) to research and study treatments and cures against opiate-induced respiratory depression. We’re working with the NIH and other biomedical research laboratories to help develop and evaluate novel treatments to help mitigate this devastating public health problem.   After the recent FDA-approved opioid overdose drug, Opvee was recently approved, we’re hopeful as we continue to research that we’ll find cures for not only opioid overdose treatments ..read more
Visit website
Promising Toxicokinetics for Treating Pulmonary Nontuberculous Mycobacteria Infection
Lovelace Biomedical
by Biotech_Research
1y ago
Melanie Doyle-Eisele, Ph.D. and Director of Life Sciences, and Philip Kuehl, Ph.D, and Director of Scientific Core Laboratories, have recently partnered with various biomedical researchers to publish the results of the recent publication entitled: Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection. Pulmonary nontuberculous mycobacteria infection, or NTM, is an opportunistic pathogen that develops continuous resistance to antibiotics. The latest publication and research on this topic investigate the usa ..read more
Visit website
So, We’re Starting a Podcast
Lovelace Biomedical
by Research_Facility
2y ago
The Lovelace Biomedical Podcast: Preclinical Research, Pharmaceutical Industry Conversations, Inside Drug Development, and More The question likely isn’t, “do you listen to podcasts?” The better question is probably, “which podcasts do you listen to?”  In today’s world of digital streaming of entertainment and media, podcasts are all the rage. From small-time individuals and organizations, or larger media outlets, to the king of all podcasters, celebrity comedian Joe Rogan pushing news and information out there for audio streaming consumption, podcasting is everywhere. No matter what the ..read more
Visit website
Hammad Irshad – Using a Degree in Engineering to Make a Difference in Public Health
Lovelace Biomedical
by Biotech_Research
2y ago
Hammad has 18 years experience, and focuses on our aerosol development and delivery for novel therapies. Hammad, tell me what you do as an aerosol scientist at Lovelace. Overall, my work leverages Lovelace’s broad capabilities in aerosol science to answer important questions that improve public health and regulations. The work is exciting because we are able to work at the cutting edge with innovators across many disciplines. I feel that the valuable collaborations we provide to our colleagues at the companies we work with really make a difference to help advance their technology. O ..read more
Visit website
PCR Development, it’s Uses, and Important Research at Lovelace Biomedical, with Bryan Gullick, PhD, Bioanalytical Research Scientist
Lovelace Biomedical
by Biotech_Research
2y ago
Staff Spotlight: Bryan Gullick, PhD, Research Scientist Bryan Gullick, PhD, Bioanalytical Research Scientist Bryan, tell us about PCR in the development and conduct of pharmacology and toxicology studies PCR assay development closely follows the in vivo studies required to support an IND. Along this path from pharmacology to toxicology the scientific team reviews, and evaluates what species to utilize. They will consider rodent and non-rodent species and the type of study (pharmacology, biodistribution and toxicology). PCR will develop assays to support each of these studies in each ..read more
Visit website
Preclinical Drug Development for a Gene Therapy Product: No Cookie Cutter Route
Lovelace Biomedical
by Biotech_Research
2y ago
Follow these critical steps on your path to IND application. By Philip J. Kuehl, PhD, Senior Scientist and Director of Scientific Core Laboratories, Lovelace Biomedical and Jacob D. McDonald , PhD, Senior Scientist and Chief Scientific Officer, Lovelace Biomedical Cell and gene therapy products are reviewed and approved through the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA). As of March 2019, there were 17 approved cellular and gene therapy products.1 With FDA’s trio of gene therapy approvals in 2017, the innovation floodga ..read more
Visit website

Follow Lovelace Biomedical on FeedSpot

Continue with Google
Continue with Apple
OR